Literature DB >> 28416417

In Vitro Evaluation of Nasogastric Tube Delivery Performance of Esomeprazole Magnesium Delayed-Release Capsules.

Alicia Hoover1, Dajun Sun2, Hong Wen2, Wenlei Jiang2, Minglei Cui2, Xiaojian Jiang2, David Keire1, Changning Guo3.   

Abstract

Enteral feeding tubes are used to deliver food or drugs to patients who cannot swallow. To deliver delayed-release drugs that are formulated as enteric coated granules to these patients via feeding tubes requires that they be suspended in water before administration. Importantly, the suspension of enteric granules in water of varying pH can cause damage to the enteric coating and affect the bioavailability of the drug. Here, analytical methods for testing acid resistance stability and particle size distribution (PSD) of esomeprazole granules were used to monitor the integrity of the granule enteric coating after water pretreatment and delivery through an oral syringe and nasogastric (NG) tube. Granules from esomeprazole magnesium delayed-release capsules were transferred to an oral syringe, suspended in water, and delivered on the bench through an NG tube. Subsequently, acid resistance stability (i.e., the amount of drug released after 2-h acid dissolution) was determined via high-performance liquid chromatography, and the PSD were measured with a laser diffraction system. All the granules demonstrated acid resistance stability when the granules were delivered immediately (0 min incubation) through the oral syringe and NG tube. In contrast, some granules demonstrated significant drug release during acid exposure after a 15-min incubation period which mimics a possible delay in delivery of the drug from the syringe by the caregiver. A bimodal PSD was observed with these granules, which was attributed to debris from damaged enteric coating and particle agglomeration. The methods developed in this study could be used to distinguish batches with suboptimal product quality for delivery using NG tubes and to confirm the substitutability of generic drug products for this alternative route of administration. Published by Elsevier Inc.

Entities:  

Keywords:  HPLC (high-performance/pressure liquid chromatography); dissolution; gastrointestinal; particle size; targeted drug delivery

Mesh:

Substances:

Year:  2017        PMID: 28416417      PMCID: PMC5564165          DOI: 10.1016/j.xphs.2017.04.008

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  16 in total

Review 1.  Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors.

Authors:  C A Stedman; M L Barclay
Journal:  Aliment Pharmacol Ther       Date:  2000-08       Impact factor: 8.171

2.  Effects of deaeration methods on dissolution testing in aqueous media: a study using a total dissolved gas pressure meter.

Authors:  Zongming Gao; Terry W Moore; William H Doub; B J Westenberger; Lucinda F Buhse
Journal:  J Pharm Sci       Date:  2006-07       Impact factor: 3.534

3.  Thoracic complications of nasogastric tube: review of safe practice.

Authors:  Jain Bhaskara Pillai; Annette Vegas; Stephanie Brister
Journal:  Interact Cardiovasc Thorac Surg       Date:  2005-06-21

Review 4.  Medication administration through enteral feeding tubes.

Authors:  Nancy Toedter Williams
Journal:  Am J Health Syst Pharm       Date:  2008-12-15       Impact factor: 2.637

5.  Administration of proton pump inhibitors in patients requiring enteral nutrition.

Authors:  Terri M Wensel
Journal:  P T       Date:  2009-03

Review 6.  Efficacy of esomeprazole in patients with acid-peptic disorders.

Authors:  Jean Beck
Journal:  Gastroenterol Nurs       Date:  2004 Mar-Apr       Impact factor: 0.978

7.  Delayed release film coating applications on oral solid dosage forms of proton pump inhibitors: case studies.

Authors:  Shahrzad Missaghi; Cara Young; Kurt Fegely; Ali R Rajabi-Siahboomi
Journal:  Drug Dev Ind Pharm       Date:  2010-02       Impact factor: 3.225

Review 8.  Proton pump inhibitors: do differences in pharmacokinetics translate into differences in clinical outcomes?

Authors:  Kwong Ming Fock; Tiing Leong Ang; Lean Choo Bee; Edmund Jon Deon Lee
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 9.  Pharmacologic properties of proton pump inhibitors.

Authors:  Lynda S Welage
Journal:  Pharmacotherapy       Date:  2003-10       Impact factor: 4.705

Review 10.  Esomeprazole.

Authors:  C M Spencer; D Faulds
Journal:  Drugs       Date:  2000-08       Impact factor: 11.431

View more
  1 in total

1.  In vitro Approaches to Support Bioequivalence and Substitutability of Generic Proton Pump Inhibitors via Nasogastric Tube Administration.

Authors:  Ping Ren; Minglei Cui; Om Anand; Li Xia; Zhuojun J Zhao; Dajun Sun; Trueman Sharp; Dale P Conner; John Peters; Wenlei Jiang; Ethan Stier; Xiaojian Jiang
Journal:  AAPS J       Date:  2017-09-06       Impact factor: 4.009

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.